The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

McGill University

Status and phase: Unknown; Phase 3

Conditions: Osteoporosis

Treatments: Drug: Alendronate

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00346190

CA-16

Details and patient eligibility

About

To determine whether administration of Alendronate early is more effective than late in the prevention of osteoporosis following a hip fracture

Sex: All

Ages: 55+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Male and Female aged > 55 Low trauma hip fracture up to 90 days Be willing to submit to periodic bone mineral density radiographic studies of the spine & 24 hr urine collection Written informed consent

Exclusion criteria

• Disorders known to affect bone metabolism Not taking bisphosphonates within last 6 months Drugs known to interfere with calcium metabolism within the lats 6 months prior to hip fracture serum calcium> 2.65 mmol/L Treatment with any investigational drug within the last 30 days

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind